RE:PanCAN 2nd annual Therapeutic Accelerator Award Goes to ONCYThrough the proposed clinical trial, the investigational virus pelareorep would be intravenously administered in patients with metastatic pancreatic cancer who have not received prior treatment, in combination with modified FOLFIRINOX chemotherapy and an immune checkpoint inhibitor, which is a class of drugs that releases the “brakes” on the immune system so that the tumor can’t protect itself from an immune attack. It’s all part of PanCAN’s bold work to expand the scope of traditional research by supporting the latest innovations within the pharmaceutical and biotech industry. “PanCAN focuses on partnering with biopharma to speed up the development of new pancreatic cancer treatments,” said PanCAN Chief Science Officer Lynn Matrisian, PhD, MBA. “We are proud to welcome Oncolytics into our community and are excited to see where this research leads.”